Orion Oyj (LON:0M2O)

London flag London · Delayed Price · Currency is GBP · Price in EUR
70.85
+0.14 (0.19%)
At close: Jan 29, 2026
37.35%
Market Cap8.47B +57.7%
Revenue (ttm)1.42B +14.0%
Net Income273.38M -5.6%
EPS1.94 -5.6%
Shares Outn/a
PE Ratio31.00
Forward PE19.01
Dividend1.41 (1.99%)
Ex-Dividend DateOct 15, 2025
Volume5,351
Average Volume45,339
Open70.93
Previous Close70.71
Day's Range70.20 - 71.05
52-Week Range46.66 - 72.80
Beta0.33
RSI57.69
Earnings DateFeb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art... [Read more]

Industry Pharmaceutical Preparations
Founded 1917
Employees 4,030
Stock Exchange London Stock Exchange
Ticker Symbol 0M2O
Full Company Profile

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial numbers in EUR Financial Statements